Thrombolysis and thrombectomy for stroke in octogenarians and nonagenarians: A regional observational study

Introduction. - Elderly patients are a growing population in stroke units, characterized by higher frailty, but underrepresented in clinical trials about acute care. We investigated efficacy of intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) in elderlies in current practice.Methods. - We assessed consecutive patients with acute ischemic stroke (AIS) hospitalized in the four stroke units of the French Northern Alps Emergency Network between 2015 and 2020. We compared baseline characteristics, early neurological evolution and outcome of patients aged 80-89 and >= 90 years old (yo).Results. - Among 8367 patients, 2744 (32.8%) were 80-89 yo and 541 (6.5%) were >= 90 yo. IVT and/or MT were performed in 787 patients >= 80 yo (632 patients aged 80-89, 155 patients aged > 90). Early neurological improvement was more frequent in patients >= 80 yo treated by IVT and/or MT compared to untreated patients (45.6% versus 38.4%, P = 0.002). After adjustment, reperfusion treatments improved likelihood of good outcome at discharge (OR = 2.0 [1.6-2.7]) and reduced in-hospital mortality (OR = 0.5 [0.4-0.7]). Age and initial NIHSS score were independent factors of poor functional outcome at discharge and inhospital mortality. The rate of successful recanalization was comparable between octogenarians and nonagenarians (87% versus 85.2%, P = 0.8). Octogenarians had better functional outcome at discharge compared to nonagenarians [modified Rankin scale (mRS) 0-2: 36% versus 25.7%, P = 0.02], whatever IVT or MT strategy. In-hospital mortality was lower for octogenarians compared to nonagenarians (19.5% versus 27.1%, P = 0.04).Discussion. - IVT and MT improve early neurological recovery and functional outcome at discharge of both octogenarians and nonagenarians in current practice. Despite a poorer outcome for nonagenarians than octogenarians, these reperfusion treatments should not be withheld on the basis of age only.# 2023 Elsevier Masson SAS. All rights reserved.